NAMUR, Belgium, Feb. 24,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) has
presented data at the World Congress of GI Endoscopy (ENDO) 2017
conference in Hyderabad, India,
from a study that confirms prior test results that the
Nu.QTM Colorectal Cancer Screening Triage test
reduces the total number of colonoscopy referrals while maintaining
high sensitivity for cancer detection.
"This is a key clinical milestone in the launch of our
Nu.QTM Triage product. This validation study, in a
second population of 1,961 subjects, greatly assists us with sales
and marketing efforts in the EU and Asia," said Louise
Day, Chief Marketing and Communications Officer at
Volition.
The lead author of the study, Dr. Marielle Herzog, commented, "This data confirms
the role that the Nu.QTM Triage test can play in
accelerating the diagnosis of colorectal cancer."
The full data can be found at
http://volitionrx.com/news/presentations
About Nu.QTM Colorectal Cancer Screening
Triage Test
There is currently a significant strain on colonoscopy capacity
which can lead to longer waiting times in European healthcare
systems due to the expansion of colorectal cancer screening
programs. Therefore, there is a pressing need to prioritise the
colonoscopy referrals for those at high risk. Volitions aims to
meet this need with its new Nu.QTM Colorectal
Cancer Screening Triage Test.
Having received a CE mark for the
Nu.QTM Colorectal Cancer Screening Triage Test in
December 2016, Volition plans to
launch the test for the European Union screening
population.
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid --
an indication that disease is present.
As cancer screening programs become more and more widespread,
our products can help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
New York, Austin, TX and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Sarah Roberts,
Vane Percy & Roberts
sarah@vanepercy.com
+44 (0)1737 821
890
|
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of the Company's bodily-fluid-based diagnostic
tests as well as the Company's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
The Company's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if we fail to develop and
commercialize diagnostic products, we may be unable to execute our
plan of operations. Other risks and uncertainties include the
Company's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
the Company's development pipeline or any other diagnostic products
the Company might develop; the Company will face fierce competition
and the Company's intended products may become obsolete due to the
highly competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in the Company's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, as well as other documents that the Company files with
the Securities and Exchange Commission. These statements are based
on current expectations, estimates and projections about the
Company's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this release, and, except as required by law, the
Company does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and
and their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limiteds-triage-test-results-validated-in-prospective-trial-300413152.html
SOURCE VolitionRx Ltd